ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Ishita Drugs approved Rs.11.75 Crore borrowings from HDFC Bank, covering a term loan and working capital facility. This is within shareholder-approved borrowing limits from its 31st AGM.
Ishita Drugs & Industries Ltd will hold a board meeting on September 22, 2026. The meeting will consider raising funds through working capital and term loans.
Ishita Drugs & Industries Ltd has issued physical letters to shareholders with weblinks for its FY 2025-26 Annual Report. The 33rd AGM is scheduled for September 30, 2026.
Ishita Drugs & Industries Ltd has scheduled its 33rd Annual General Meeting for September 30, 2026. The book closure is set from September 24 to September 30, 2026.
Ishita Drugs and Industries Limited has re-appointed Abha Agrawal as a Non-Executive Non-Independent Director, effective October 1, 2026.
Ishita Drugs & Industries Ltd reported revenue from operations of ₹3.1 Cr (-42.6% YoY) and net profit of ₹0.2 Cr (-33.3% YoY) for Q1 FY27.
Ishita Drugs & Industries has scheduled a board meeting for August 8, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Ishita Drugs & Industries Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI regulations.
Ishita Pharmaceuticals acquired 223 shares of Ishita Drugs & Industries Ltd via open market. The transaction value is approximately ₹0.000223 Crore.
Ishita Drugs & Industries Ltd reported revenue from operations of ₹3.1 Cr (-32.6% YoY) and net profit of ₹0.2 Cr (-33.3% YoY) for Q4 FY26.
Ishita Drugs & Industries approved its FY26 audited financial results showing annual revenue of ₹14.66 Crore. The board also recommended convening the 33rd Annual General Meeting.
Ishita Drugs & Industries Ltd scheduled a board meeting for May 30, 2026. Directors will review audited financial results for the fiscal year ended March 2026.
Ishita Drugs & Industries Ltd has disclosed that it is 'Not a Large Corporate' as of March 31, 2026, under SEBI's debt-raising framework. The company reported outstanding borrowings of ₹0.14 Crore. Consequently, it is not required to file specific disclosures for the Financial Year 2025-26.
Ishita Drugs & Industries Ltd informed the BSE that the Annual Secretarial Compliance Report for FY26 is not applicable. The company is exempt under Regulation 15(2) of SEBI LODR as its paid-up equity capital is Rs. 2.99 Crore and net worth is Rs. 10.78 Crore, both below the mandatory reporting thresholds.
Ishita Drugs & Industries Ltd submitted a NIL statement of deviation or variation under SEBI Regulation 32(1). The company confirmed it raised no funds through public, rights, or preferential issues during FY 2025-26. This routine regulatory filing maintains compliance and transparency regarding the company's capital raising activities.